AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34083595 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypercapnia
Number of subjects: 0
Study 34083595 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34083618 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day for 15 weeks
Number of subjects: 20
Study 34083737 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American men (AAM)
Number of subjects: 1152
Study 34083737 — intervention group
Group type: COMPARATOR
Intervention: European-American men (EAM)
Number of subjects: 1152
Study 34084608 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotechnology-based therapy (seizure advisory system)
Number of subjects: 400
Study 34084993 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs)
Number of subjects: 0
Study 34084993 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain HMOs and bioactive proteins
Number of subjects: 0
Study 34085287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 609
Study 34085287 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus clomiphene
Number of subjects: 609
Study 34085287 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus follicle aspiration plus ovulation induction
Number of subjects: 609
Study 34085287 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus laparoscopic ovarian drilling (LOD)
Number of subjects: 609
Study 34085287 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (with or without LOD)
Number of subjects: 609
Study 34085287 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, no treatment, or conventional therapies)
Number of subjects: 609
Study 34085900 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster dose
Number of subjects: 91
Study 34085900 — intervention group
Group type: COMPARATOR
Intervention: MCV4-TT primed group
Number of subjects: 91
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2380
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and history of microvascular complications
Number of subjects: 2380
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 2380
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP, AST, eGFR (CKD-EPI)
Number of subjects: 2380
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytopenia
Number of subjects: 2380
Study 34085949 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia and elevated plasma glucose concentration
Number of subjects: 2380
Study 34086122 — intervention group
Group type: EXPERIMENTAL
Intervention: PHGG plus sodium hyaluronate (PHGG+)
Number of subjects: 34
Study 34086171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel 80 mg/m² with carboplatin, trastuzumab, and pertuzumab (wPCbTP)
Number of subjects: 30
Study 34086266 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 group (n = 60)
Number of subjects: 60
Study 34086408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-based reduced-intensity conditioning (RIC) regimen
Number of subjects: 9
Study 34086494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Number of subjects: 0
Study 34086494 — intervention group
Group type: COMPARATOR
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0
Study 34086503 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 management in children with diabetes
Number of subjects: 22820
Study 34086503 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control measures
Number of subjects: 22820
Study 34086623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Evaluation of Disability Index-Computer Adapted Test (PEDI-CAT) mobility domain (PEDI-mob)
Number of subjects: 54
Study 34086718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0
Study 34086718 — intervention group
Group type: COMPARATOR
Intervention: Stable Coronary Artery Disease (CAD) subjects
Number of subjects: 0
Study 34086865 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib/ofatumumab (IO)
Number of subjects: 51
Study 34086865 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib/obinutuzumab (IG)
Number of subjects: 51
Study 34086865 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax/obinutuzumab (AG)
Number of subjects: 51
Study 34086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 51
Study 34086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation due to uMRD
Number of subjects: 51
Study 34086888 — intervention group
Group type: COMPARATOR
Intervention: Stage 0-1 (no cardiac damage or left ventricular damage)
Number of subjects: 1156
Study 34086888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 (left atrial or mitral valve damage)
Number of subjects: 1156
Study 34086888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 (pulmonary vasculature or tricuspid valve damage)
Number of subjects: 1156
Study 34086888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 4 (right ventricular damage or low-flow state)
Number of subjects: 1156
Study 34086888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3b, Stage 4b, and Stage 4c
Number of subjects: 1156
Study 34086888 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cardiac damage (severe pulmonary hypertension or RV dysfunction)
Number of subjects: 1156
Study 34087573 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg, twice daily)
Number of subjects: 252
Study 34087863 — intervention group
Group type: EXPERIMENTAL
Intervention: NexfinTM (beat-to-beat noninvasive blood pressure monitoring)
Number of subjects: 174
Study 34087863 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oscillometry (conventional method)
Number of subjects: 174
Study 34087940 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fructose-containing sugars in substitution trials
Number of subjects: 2763
Study 34087940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) in substitution design
Number of subjects: 2763
Study 34087940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweets and desserts in substitution design
Number of subjects: 2763
Study 34087940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) in addition trials
Number of subjects: 2763
Study 34087940 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% fruit juice in addition trials
Number of subjects: 2763
Study 34087943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KetoCal® KD, 90% fat, 8% carbohydrate, 2% protein)
Number of subjects: 12
Study 34087943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KetoCal® KD)
Number of subjects: 12
Study 34087943 — intervention group
Group type: COMPARATOR
Intervention: Radiation with concurrent platinum-based chemotherapy
Number of subjects: 12
Study 34087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal flap (DIEP, fTRAM, pTRAM)
Number of subjects: 121
Study 34087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal flap (LD, TDAP)
Number of subjects: 121
Study 34087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Other (TMG, implant)
Number of subjects: 121
Study 34087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain
Number of subjects: 121
Study 34088579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive multiple sclerosis (aMS)
Number of subjects: 2158
Study 34088579 — intervention group
Group type: COMPARATOR
Intervention: Non-aggressive multiple sclerosis (non-aMS)
Number of subjects: 2158
Study 34088656 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT program
Number of subjects: 15
Study 34088656 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 15
Study 34088656 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 15
Study 34088726 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 80
Study 34088733 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative iron administration
Number of subjects: 0
Study 34088741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and radiotherapy
Number of subjects: 17
Study 34088789 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lockdown period
Number of subjects: 311
Study 34088831 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-based rational combinations
Number of subjects: 0
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for more than 24 hours
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher severity of illness (APACHE III)
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission diagnosis (cardiac arrest)
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission diagnosis (sepsis)
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission diagnosis (trauma)
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission diagnosis (lung transplant)
Number of subjects: 628
Study 34089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including age, illness severity, and admission diagnosis
Number of subjects: 628
Study 34089087 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS protocol (US+)
Number of subjects: 100
Study 34089087 — intervention group
Group type: COMPARATOR
Intervention: No POCUS (US-)
Number of subjects: 100
Study 34089097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectoin
Number of subjects: 0
Study 34089325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program, 12-week exercise-based intervention.
Number of subjects: 359
Study 34089500 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement of double-stapled anastomosis using circular mucosa plication and vacuum drainage with povidone-iodine-soaked sponge
Number of subjects: 54
Study 34089610 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection (COVID-19 convalescent donors)
Number of subjects: 228
Study 34089650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (6 mg equivalent for cohort 1, 12 mg for cohort 2)
Number of subjects: 20
Study 34089650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (12 mg)
Number of subjects: 20
Study 34089650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 20
Study 34089739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adherence to Low Tidal Volume Ventilation (LPV)
Number of subjects: 2466
Study 34089739 — intervention group
Group type: COMPARATOR
Intervention: Center management practices
Number of subjects: 2466
Study 34089751 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative stereotactic ablative body radiotherapy (SBRT) as 5 fractions of 7 Gy with dose reduction to 5 fractions of 5 Gy on tumor margins.
Number of subjects: 14
Study 34089751 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative conventional radiotherapy as standard compartmental irradiation in 25 fractions of 2 Gy, starting 5-8 weeks after surgery.
Number of subjects: 14
Study 34089855 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) therapy
Number of subjects: 748
Study 34089982 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIa-AT complex (Q2 and Q3 quartiles)
Number of subjects: 114
Study 34089982 — intervention group
Group type: EXPERIMENTAL
Intervention: FIXa-AT complex
Number of subjects: 114
Study 34089982 — intervention group
Group type: EXPERIMENTAL
Intervention: TAT complex
Number of subjects: 114
Study 34090143 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Molecular Score (OMm)
Number of subjects: 404
Study 34090143 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score (OM)
Number of subjects: 404
Study 34090143 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR scores (OMm and OM)
Number of subjects: 404
Study 34090525 — intervention group
Group type: EXPERIMENTAL
Intervention: Training webinar
Number of subjects: 19
Study 34090525 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + implementation enhanced resources (including a champion at each site and monthly peer support consultation calls)
Number of subjects: 19
Study 34090853 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote training for clinician trainers
Number of subjects: 26
Study 34090853 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for able-bodied trainees
Number of subjects: 26
Study 34090865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanotechnology-based strategies for cancer diagnosis and therapy
Number of subjects: 0
Study 34090871 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566)
Number of subjects: 750
Study 34090871 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated patients
Number of subjects: 750
Study 34090871 — intervention group
Group type: COMPARATOR
Intervention: Inoperable patients
Number of subjects: 750
Study 34090871 — intervention group
Group type: COMPARATOR
Intervention: Operable patients who did not undergo surgery (n = 88)
Number of subjects: 750
Study 34090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle ultrasound measurements during spontaneous breathing trial
Number of subjects: 57
Study 34090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thickening fraction of transversus abdominis, internal oblique, and rectus abdominis during cough
Number of subjects: 57
Study 34090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle thickening on ultrasound
Number of subjects: 57
Study 34090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal muscle ultrasound measurements
Number of subjects: 57
Study 34090872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced abdominal muscle thickening during cough
Number of subjects: 57
Study 34091488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin
Number of subjects: 0
Study 34091488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (FD)
Number of subjects: 2916
Study 34091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic dyspepsia (OD)
Number of subjects: 2916
Study 34091519 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori infection rate in FD patients
Number of subjects: 2916
Study 34091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent spicy food consumption
Number of subjects: 2916
Study 34091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of deep well water
Number of subjects: 2916
Study 34091540 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Transit system (Motilis SA, Lausanne, Switzerland)
Number of subjects: 21
Study 34091867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0
Study 34091867 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34091914 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 150
Study 34091914 — intervention group
Group type: COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Number of subjects: 150
Study 34091914 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 150
Study 34091914 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 150
Study 34091914 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 150
Study 34091914 — intervention group
Group type: COMPARATOR
Intervention: HIFU
Number of subjects: 150
Study 34092091 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve self-expanding supra-annular TAVR
Number of subjects: 639
Study 34092097 — intervention group
Group type: EXPERIMENTAL
Intervention: Second transcatheter aortic valve replacement (TAVR)
Number of subjects: 172
Study 34092119 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34092158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin pharmacotherapy, dosage and duration not available
Number of subjects: 0
Study 34092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional prevention programme based on temporal patterns
Number of subjects: 0
Study 34092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Audits and seminars of healthcare professionals
Number of subjects: 0
Study 34092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Component and Single Cosinor analyses
Number of subjects: 0
Study 34092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study based on focus groups
Number of subjects: 0
Study 34092233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS) monotherapy (300 mg/kg)
Number of subjects: 0
Study 34092233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS) in combination with αPD1 + αCTLA4
Number of subjects: 0
Study 34092233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib (RGS)
Number of subjects: 0
Study 34092549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subanesthetic intravenous ketamine and therapist-administered e-CBT over 14 weeks
Number of subjects: 20
Study 34092549 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group receiving the experimental treatment after 14 weeks
Number of subjects: 20
Study 34093204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mudan Granule combined with Methylcobalamin
Number of subjects: 0
Study 34093204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34093444 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (median dose of 50 μg)
Number of subjects: 842
Study 34093444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842
Study 34093444 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 842
Study 34093762 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 161
Study 34093762 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 161
Study 34093873 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 0
Study 34094549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) therapy
Number of subjects: 0
Study 34094549 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium and long treatment regimens of low-dose IL-2
Number of subjects: 0
Study 34094549 — intervention group
Group type: EXPERIMENTAL
Intervention: Long treatment regimen of low-dose IL-2
Number of subjects: 0
Study 34094939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative B-mode ultrasound guided surgery
Number of subjects: 50
Study 34094939 — intervention group
Group type: COMPARATOR
Intervention: Standard neuronavigation surgery
Number of subjects: 50
Study 34095161 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy, details on dosage and duration not available
Number of subjects: 0
Study 34095161 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34095178 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation, details on dosage and duration not available
Number of subjects: 0
Study 34095178 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34095266 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) assessment
Number of subjects: 0
Study 34095450 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO levels in patients with persistent AF
Number of subjects: 78
Study 34095450 — intervention group
Group type: COMPARATOR
Intervention: TMAO levels in patients with paroxysmal AF
Number of subjects: 78
Study 34096037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal water-contrast transvaginal ultrasonography (RWC-TVS)
Number of subjects: 281
Study 34096037 — intervention group
Group type: COMPARATOR
Intervention: Sonovaginography (SVG)
Number of subjects: 281
Study 34096037 — intervention group
Group type: EXPERIMENTAL
Intervention: RWC-TVS
Number of subjects: 281
Study 34096037 — intervention group
Group type: COMPARATOR
Intervention: RWC-TVS and SVG
Number of subjects: 281
Study 34096130 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use for informational support
Number of subjects: 14
Study 34096130 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use for emotional support
Number of subjects: 14
Study 34096130 — intervention group
Group type: EXPERIMENTAL
Intervention: Information gathering through social media
Number of subjects: 14
Study 34096130 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about privacy vs. transparency
Number of subjects: 14
Study 34096320 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive
Number of subjects: 155
Study 34096341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude Spectral Area (AMSA)
Number of subjects: 50
Study 34096690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib (960 mg orally once daily)
Number of subjects: 126
Study 34096876 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based indoor 6-minute walk test (6MWT)
Number of subjects: 30
Study 34096876 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based outdoor 6-minute walk test (6MWT)
Number of subjects: 30
Study 34096876 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of the app
Number of subjects: 30
Study 34096876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry during 6MWTs
Number of subjects: 30
Study 34096986 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of WWE taking ASMs
Number of subjects: 292
Study 34096986 — intervention group
Group type: COMPARATOR
Intervention: Children of healthy women
Number of subjects: 292